TY  - CHAP
AU  - Victoria Chagoya de Sánchez
AU  - Lucía Yañez-Maldonado
AU  - Susana Vidrio-Gómez
AU  - Lidia Martínez
AU  - Jorge Suárez
AU  - Alberto Aranda-Fraustro
AU  - Juan Carlos Torres
AU  - Gabriela Velasco-Loyden
ED  - Manuela Fiuza
Y1  - 2012-03-28
PY  - 2012
T1  - Role of Nitric Oxide in Isoproterenol-Induced Myocardial Infarction
N2  - The possibility of getting a cardiovascular disease or cancer increases with advancing age. At the same time, relevant improvements in cancer therapy have resulted in the improvement of quality of life and the increasement of the survival rate of such patients. As a result we have larger number of patients that experience the cardiac side effects of chemotherapy. The extent of cardiotoxicity is variable, depending on the type of drug used, combination with other drugs, prior mediastinal radiotherapy and the presence of cardiovascular risk factors or history of heart disease. Early detection of the patients proneness for developing cardiotoxicity is the  key issue to decrease morbidity and mortality. It also facilitates more tailored therapeutic interventions. Therefore, the collaboration and interaction of cardiology and oncology may contribute to reducing the cardiovascular adverse effects and improving the results in the treatment of patients with cancer.
BT  - Cardiotoxicity of Oncologic Treatments
SP  - Ch. 2
UR  - https://doi.org/10.5772/34505
DO  - 10.5772/34505
SN  - 
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-26
ER  -